Figure 6.

Wip1 inhibition enhances tumor response to cisplatin in vivo. (A) UM-SCC-11B cells were implanted into nude mice to form tumors. As described in Materials and Methods, mice were then treated with As₂O₃ and cisplatin with five daily injections, as indicated. Tumor volume was measured, and tumors were excised and weighed. Statistical significance was determined by Student’s t-test (N≥4 per group) (B) UM-SCC-11B cells with control (ctr) shRNA or Wip1 shRNA were implanted into nude mice to form xenograft tumors. Once the tumor reached 50 mm³ in volume, the mouse was then treated with cisplatin as in panel A, and tumor weight was determined. Statistical significance was determined by Student’s t-test (N=4 per group) (C) As in panel A & B, UM-SCC-11B cells were implanted into nude mice, which were then treated with cisplatin alone (control), or cisplatin with CCT. Tumor weight was measured. Statistical significance was determined by Student’s t-test (N=5 per group).